Drilling set to commence at Hardey’s Lloyd’s Copper Mine

Published 13-JUN-2018 12:15 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Hardey Resources Limited (ASX:HDY) is soon to commence a new exploration program at its flagship Burraga Project in the Lachlan Fold Belt in NSW, with drilling to focus on the historic Lloyd’s copper mine.

Armed with a significant exploration budget for 2018, HDY continues to progress all of the assets within its portfolio, yet it has made the strategic decision to direct its focus to Lloyd’s copper mine with drilling set to begin, ahead of schedule, in the upcoming September quarter.

This decision was based on the outlook for copper and the geological potential recognised around the historic workings at the mine. All the preparatory work for a significant drilling program at its Burraga project is now complete.

HDY’s objectives for the exploration program at Lloyd’s include:

  • Building on the results of previous drilling;
  • Further extending known mineralisation;
  • Testing the model of the ore body, which suggests that mineralisation has been deposited in a series of stacked lenses; and
  • Testing for mineralisation at depth and to the eastern extent of the ore body as predicted by the stacked lens model.

However it is an early stage of this company’s development and if considering this stock for your portfolio you should take all public information into account and seek professional financial advice.

Ore body model at Lloyd’s

In order to increase its understanding of the Lloyd’s ore body HDY embracing cutting-edge technology, namely hyperspectral ore body modelling.

Hyperspectral analysis of existing drill core and chips will be used in conjunction with existing GIS and geochemical data to provide a holistic model of the Lloyd’s ore body and its alteration halo.

The upcoming drilling will provide additional data for the hyperspectral model of the Lloyd’s site.

This remodelling of Lloyd’s ore body will help to guide future drilling programs. This type of analysis has proven to be one of the most accurate and cost-effective exploration tools for assessing structurally complex ore bodies such as Lloyd’s.

For the remainder of the year, HDY plans to drill further exploration targets across the Burraga Project. The hyperspectral model will drive future target generation for drilling, whilst the team is also in the process of finalising holes at Hackneys and Isabella within the Burraga leases.

A specialist consultant who has worked for several large ASX listed miners has been engaged to produce a model of the Lloyd’s site which will lead to better exploration strategy. The consultant has produced similar models of many globally significant ore bodies and continues to work with many major resources companies.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X